Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)
- Registration Number
- NCT00637442
- Lead Sponsor
- University Hospital, Bonn
- Brief Summary
Examination of the correlation between the cerebral bloodflow and the clinical change under treatment with Reminyl retard® and the prediction of clinical change by measuring the cerebral bloodflow in patients with mild to moderate Alzheimer's Disease
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Possible Alzheimer's Disease according to ICD-10 and NINCDS-ADRDA
- Underwritten study consent
- No treatment with acetylcholinesterase inhibitors
- Mini-Mental-State Examination: 12-25 points
- Age: 50-80 Years
- Orale contraception for women of child-bearing age
Exclusion Criteria
- Mental Disorders
- Other Diseases of the CNS
- Severe Illness
- Contraindication for MRI-Scan
- Contraindication for Galantamin (Reminyl retard®)
- Participation at other clinical trials
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description CASL-MRI Reminyl retard Drug monitoring with CASL-MRI for new diagnosed patients with mild to moderate Alzheimer's Disease treated with Reminyl
- Primary Outcome Measures
Name Time Method Cerebral perfusion baseline and after 12 weeks
- Secondary Outcome Measures
Name Time Method Change of Alzheimer Disease Assessment Scale, cognitive part (ADAScog) baseline, after 12 and 24 weeks Alzheimer's Disease Functional Assessment and Change Scale (ADFACS) baseline, after 12 and 24 weeks Neuropsychiatric Inventory (NPI) baseline, after 12 and 24 weeks Mini-Mental-Status-Examination (MMSE) baseline, after 12 and 24 weeks
Trial Locations
- Locations (1)
Department of Psychiatry, University Bonn
🇩🇪Bonn, Germany